THE INVESTOR

메뉴열기

Celltrion’s Godex sales outpace Daewoong Pharma’s Ursa

PUBLISHED : August 30, 2017 - 11:34

UPDATED : August 30, 2017 - 11:34

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Sales of liver drug Godex manufactured by Celltrion have topped the local market, far outpacing sales for its rival Ursa by Daewoong Pharma, industry data showed on Aug. 30.

Godex, widely used in patients with chronic liver disease who show elevated liver enzymes, raked in 26.2 billion won (US$23.30) in sales during the first half of this year, compared with 18.7 billion won by Ursa, they showed.

Celltrion attributed the increase of sales as Godex is now subscribed not only by an internal medicine department but by doctors practicing family medicine.

Annual sales of Godex outpaced Ursa for the first time last year with the gap forecast to be further widened down the road, market watchers said.

By Alex Lee and newswires (alexlee@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
JUVENILE PROTECTION MANAGER : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.